Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atrys HealthXMAD:ATRY +3.32%62 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates XMAD:ATRY with a GF Score™ of 62/100 and a GF Value™ of €3.18 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,135 Biotechnology companies, Atrys Health ranks worse than 88105.64% on this metric.
During the past 12 months, Atrys Health's average EBITDA Per Share Growth Rate was -158.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Atrys Health was 58.20% per year. The lowest was -14.70% per year. And the median was 10.50% per year.
Atrys Health (XMAD:ATRY) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Atrys Health 3-Year EBITDA Growth Rate Related Terms
XMAD:ATRY vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Atrys Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Atrys Health's 3-Year EBITDA Growth Rate falls into.
Atrys Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Atrys Health (XMAD:ATRY) has a 3-Year EBITDA Growth Rate of 0.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Atrys Health and its competitors. According to the industry distribution chart, Atrys Health ranks #999999 out of 1135 companies in the Biotechnology industry.
Is Atrys Health's 3-Year EBITDA Growth Rate too high?
Atrys Health's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Atrys Health ranks #999999 out of 1135 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atrys Health has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #999999 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Atrys Health in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Atrys Health and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrys Health's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.18, compared to a current price of €2.65 — trading 16.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Atrys Health's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.65 is trading 16.8% below its estimated GF Value™ of €3.18.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: €3.18 vs. price of €2.65 (16.8% below fair value)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
62GF Score
Get the complete analysis for XMAD:ATRY
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
